PDCD1 and melanoma: Notably, they demonstrated complete regression of murine melanoma (B16.OVA) tumors, and Improved survival of those animals treated first with intratumoral viral injections, followed by systemically-delivered anti-PD-1 antibodies (prime-boost approach) [85].